Open AccessEncapsulating Halofuginone Hydrobromide in TPGS Polymeric Micelles Enhances Efficacy Against Triple-Negative Breast Cancer Cells
Author(s) -
Runan Zuo,
Jingjing Zhang,
Xinhao Song,
Shiheng Hu,
Xiaona Gao,
Junqi Wang,
Hui Ji,
Chunlei Ji,
Peng Lin,
Hongbin Si,
Gonghe Li,
Kun Fang,
Junren Zhang,
Shanxiang Jiang,
Dawei Guo
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s289096
Subject(s) - in vivo , polyethylene glycol , poloxamer , triple negative breast cancer , chemistry , pharmacology , micelle , zeta potential , paclitaxel , sulforhodamine b , drug delivery , materials science , breast cancer , in vitro , cytotoxicity , cancer , medicine , nanoparticle , biochemistry , nanotechnology , organic chemistry , polymer , aqueous solution , microbiology and biotechnology , copolymer , biology
Halofuginone hydrobromide (HF) is a synthetic analogue of the naturally occurring quinazolinone alkaloid febrifugine, which has potential therapeutic effects against breast cancer, however, its poor water solubility greatly limits its pharmaceutical application. D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) is a water-soluble derivative of vitamin E, which can self-assemble to form polymeric micelles (PMs) for encapsulating insoluble anti-tumor drugs, thereby effectively enhancing their anti-cancer effects.